Clinical utility of complement‐dependent C3d assay in kidney recipients presenting with late allograft dysfunction

The objective of this study was to evaluate the utility of a complement‐dependent C3d assay to risk stratify donor‐specific antibodies (DSA) in a multicenter cohort of kidney recipients presenting with new‐onset clinical dysfunction. A total of 106 subjects with evidence of DSA at a mean period of 5.3 ± 5.0 years posttransplant underwent testing using C3d reagents. C3d positivity was strongly associated with both the peak and sum IgG DSA MFI, with 98.3% (n = 57/58) of strongly reactive sera (peak MFI > 10 000) eliciting a positive signal. Patients with C3d+ DSA had a higher creatinine (P = .03), more significant graft fibrosis (P = .035), and a faster rate of graft loss posttest compared to those with C3d‐ DSA (P = .05). Subanalysis of patients with low‐moderate level DSA confirmed the inferior outcome associated with C3d positivity. Despite the prognostic value of C3d as a stand‐alone test, the assay did not provide independent risk prediction after incorporation of graft fibrosis in a multivariate model (P = .94). Overall, C3d offered limited discriminatory value for strong DSA with peak IgG MFI > 10 000 and in patients where histologic data is available, but its utilization may be considered in those with low‐moderate level DSA and where an allograft biopsy is not accessible.

[1]  M. Posch,et al.  A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. , 2017, Journal of the American Society of Nephrology : JASN.

[2]  G. Serban,et al.  Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays , 2017, Transplantation direct.

[3]  P. Nickerson,et al.  Evaluation of C1q Status and Titer of De Novo Donor‐Specific Antibodies as Predictors of Allograft Survival , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  P. Halloran,et al.  Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection—Results of a Cross-Sectional Screening Study , 2017, Transplantation.

[5]  G. Ghiggeri,et al.  Acquisition of C3d‐Binding Activity by De Novo Donor‐Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  O. Toupance,et al.  One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial , 2016, Transplantation.

[7]  P. Nickerson,et al.  Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. , 2016, Journal of the American Society of Nephrology : JASN.

[8]  J. Friedewald,et al.  Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  D. Kaufman,et al.  C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection , 2015, Transplantation.

[10]  J. Scoazec,et al.  Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. , 2015, Journal of the American Society of Nephrology : JASN.

[11]  S. Schaub,et al.  Determinants of C1q Binding in the Single Antigen Bead Assay , 2014, Transplantation.

[12]  Piet Gros,et al.  Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.

[13]  E. Reed,et al.  Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms , 2014, Current opinion in organ transplantation.

[14]  J. Pascual,et al.  Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? , 2013, Transplant immunology.

[15]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[16]  A. Hartmann,et al.  Early Versus Late Acute Antibody-Mediated Rejection in Renal Transplant Recipients , 2013, Transplantation.

[17]  C. Haisch,et al.  The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes , 2013, Transplantation.

[18]  J. Papadimitriou,et al.  Antibody-Mediated Allograft Rejection: Morphologic Spectrum and Serologic Correlations in Surveillance and for Cause Biopsies , 2013, Transplantation.

[19]  G. Ghiggeri,et al.  Posttransplant De Novo Donor‐Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody‐Mediated Rejection , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  M. Verhaar,et al.  Pretransplant Donor‐Specific HLA Class‐I and ‐II Antibodies Are Associated With an Increased Risk for Kidney Graft Failure , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  D. Tyan,et al.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. , 2011, Human immunology.

[22]  S. Busque,et al.  C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation , 2011, Transplantation.

[23]  G. Berry,et al.  Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  D. Rush,et al.  Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure , 2010, Transplantation.

[25]  B. Kasiske,et al.  Pathological and Clinical Characterization of the ‘Troubled Transplant’: Data from the DeKAF Study , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  N. Banner,et al.  C4d Fixing, Luminex Binding Antibodies—A New Tool for Prediction of Graft Failure After Heart Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  C. Zeng,et al.  Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. , 2006, Kidney international.

[28]  F. Claas,et al.  Human Leukocyte Antigen Antibodies and Human Complement Activation: Role of IgG Subclass, Specificity, and Cytotoxic Potential , 2004, Transplantation.

[29]  T. Fuller,et al.  HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure. , 1997, Human immunology.

[30]  T. Walley,et al.  Outcomes , 1995, Too Many Lawyers?.

[31]  J. Lan,et al.  Clinical Utility of Complement Dependent Assays in Kidney Transplantation. , 2018, Transplantation.

[32]  J. Lunz,et al.  Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.